Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM, Lieberman J, Miller CJ, Moore JP, Mosier DE, Richman DD, Schooley RT, Springer MS, Veazey RS, Wainberg MA (2008) Whither or wither microbicides? Science 321:532–534.

Abrams DI, Shade SB, Couey B, Couey P, McCune JM, Lo J, Bacchetti P, Chang B, Epling L, Liegler T, Grant RM (2007) Dehydroepiandrosterone (DHEA) effects on HIV replication and host immunity: A randomized placebo-controlled study. AIDS Res. Hum. Retroviruses 23:77–85.

Bourara K, Liegler TJ, Grant RM (2007) Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Path. 3:1477–1485.

Colfax GN, Vittinghoff E, Grant R, Lum P, Spotts G, Hecht FM (2007) Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS 21:239–241.

Grant RM (2007) Research in situ. Nat. Methods 4:887–890.

Barbour JD, Hecht FM, Little SJ, Markowitz M, Daar ES, Kelleher AD, Routy JP, Campbell TB, Rosenberg ES, Segal MR, Weidler J, Grant RM (2006) Greater CD4 T-cell gains after one year of antiretroviral therapy are associated with lower HIV-1 pol replication capacity. AIDS 20:2123–2125.

Gange SJ, Schneider MF, Grant RM, Liegler T, French A, Young M, Anastos K, Wilson TE, Ponath C, Greenblatt R (2006) Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure. J. Acquir. Immune Defic. Syndr. 41:68–74.

Grant RM, Wainberg MA (2006) Chemoprophylaxis of HIV infection: moving forward with caution. J. Infect. Dis. 194:874–876.

Lama JR, Sanchez J, Suarez L, Caballero P, Laguna A, Sanchez JL, Whittington WL, Celum C, Grant RM (2006) Linking HIV and antiretroviral drug resistance surveillance in Peru: A model for a third-generation HIV sentinel surveillance. J. Acquir. Immune Defic. Syndr. 42:501–505.

Levy V, Grant RM (2006) Antiretroviral therapy for hepatitis B virus-HIV–coinfected patients: promises and pitfalls. Clin. Infect. Dis. 43:904–910. Erratum in: Clin. Infect. Dis. 43:1376.

Liu AY, Grant RM, Buchbinder SP (2006) Preexposure prophylaxis for HIV: unproven promise and potential pitfalls. JAMA 296:863–865.

Sanchez MS, Grant RM, Porco TC, Getz WM (2006) HIV drug-resistant strains as epidemiological sentinels. Emerg. Infect. Dis. 12:191–197.

Truong HH, Grant RM, McFarland W, Kellogg T, Kent C, Louie B, Wong E, Klausner JD (2006) Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance. AIDS 20:2193–2197.

Truong HH, Kellogg T, Klausner JD, Katz MH, Dilley J, Knapper K, Chen S, Prabhu R, Grant RM, Louie B, McFarland W (2006) Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting? Sex. Transm. Infect. 82:461–466.

Barbour JD, Grant RM. The role of viral fitness in HIV pathogenesis. Curr. HIV/AIDS Rep. 2:29–34, 2005.

Chin-Hong PV, Deeks SG, Liegler T, Hagos E, Krone MR, Grant RM, Martin JN. High-risk sexual behavior in adults with genotypically proven antiretroviral-resistant HIV infection. J. Acquir. Immune Defic. Syndr. 40:463–471, 2005.

Deeks SG, Hoh R, Neilands TB, Liegler T, Aweeka F, Petropoulos CJ, Grant RM, Martin JN. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J. Infect. Dis. 192:1537–1544, 2005.

Grant RM, Buchbinder S, Cates W Jr., Clarke E, Coates T, Cohen MS, Delaney M, Flores G, Goicochea P, Gonsalves G, Harrington M, Lama JR, MacQueen KM, Moore JP, Peterson L, Sanchez J, Thompson M, Wainberg MA. AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science 309:2170–2171, 2005.

Hecht FM, Grant RM. Resistance testing in drug-naive HIV-infected patients: is it time? Clin. Infect. Dis. 41:1324–1325, 2005.

Klausner JD, Grant RM, Kent CK. Detection of acute HIV infections. N. Engl. J. Med. 353:631–633, 2005.

Neuenburg JK, Furlan S, Bacchetti P, Price RW, Grant RM. Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy. AIDS 19:1351–1359, 2005.

Neuenburg JK, Cho TA, Nilsson A, Bredt BM, Hebert SJ, Grant RM, Price RW. T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infection. J. AIDS 39:16–22, 2005.

Roland ME, Neilands TB, Krone MR, Katz MH, Franses K, Grant RM, Busch MP, Hecht FM, Shacklett BL, Kahn JO, Bamberger JD, Coates TJ, Chesney MA, Martin JN. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin. Infect. Dis. 41:1507–1513, 2005.

Sanchez MS, Grant RM, Porco TC, Gross KL, Getz WM. A decrease in drug resistance levels of the HIV epidemic can be bad news. Bull. Math. Biol. 67:761–782, 2005.

Angel JB, Hu YW, Kravcik S, Tsui R, Lee KH, Barbour J, Balaskas E, Branson BM, Delwart EL, Grant RM. Virological evaluation of the 'Ottawa case' indicates no evidence for HIV-1 superinfection. AIDS 18:331–334, 2004.

Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, Busch MP, Petropoulos CJ, Hellmann NS, Kahn JO, Grant RM. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J. Infect. Dis. 190:251–256, 2004.

Barbour JD, Grant RM. The clinical implications of reduced viral fitness. Curr. Infect. Dis. Rep. 6:151–158, 2004.

Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, Segal MR, Petropoulos CJ, Grant RM. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 18:1683–1689, 2004.

Gross KL, Porco TC, Grant RM. HIV-1 superinfection and viral diversity. AIDS 18:1513–1520, 2004. Neuenburg JK, Sinclair E, Nilsson A, Kreis C, Bacchetti P, Price RW, Grant RM. HIV-producing T cells in cerebrospinal fluid. J. Acquir. Immune Defic. Syndr. 37:1237–1244, 2004.

Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ. Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection. PLoS Med. 1(3):e64. Epub Dec. 28, 2004.

Porco TC, Martin JN, Page-Shafer KA, Cheng A, Charlebois E, Grant RM, Osmond DH. Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 18:81–88, 2004.

Segal MR, Barbour JD, Grant RM. Relating HIV-1 sequence variation to replication capacity via trees and forests. Stat. Appl. Genet. Mol. Biol. 3(1):Article 2, 2004. http://www.bepress.com/sagmb/vol3/iss1/art2

Tsui R, Herring BL, Barbour JD, Grant RM, Bacchetti P, Kral A, Edlin BR, Delwart EL. Human immunodeficiency virus type 1 superinfection was not detected following 215 years of injection drug user exposure. J. Virol.78:94–103, 2004.

Asmuth DM, Kalish LA, Laycock ME, Murphy EL, Mohr BA, Lee TH, Gallarda J, Giachetti C, Dollard SC, van der Horst CH, Grant RM, Busch MP [for the Viral Activation Transfusion Study (VATS) Group] (2003) Absence of hepatitis B and C virus, human T-cell leukemia virus I/II, and human herpesvirus-8 activation following allogeneic red blood cell transfusion in patients with advanced HIV-1 infection. Transfusion 43:451–458.

Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, Perry S, Conroy KN, Clark R, Guzman D, Zolopa A, Moss A (2003) High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17:1925–1932.

D’Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. (2003) Drug resistance mutations in HIV-1. Topics HIV Med. 11:92–96.

Deeks SG, Grant RM, Wrin T, Paxinos E, Liegler T, Hoh R, Martin JN, Petropoulos CJ (2003) Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS 17:361–370.

Grant RM, Kuritzkes DR, Johnson VA, Mellors JW, Sullivan JL, Swanstrom R, D’Aquila RT, Van Gorder M, Holodniy M, Lloyd RM, Jr., Reid C, Morgan GF, Winslow DL. (2003) Accuracy of the TRUGENE HIV-1 Genotyping Kit. J. Clin. Microbiol. 41:1586–1593.

Hayden MS, Palacios EH, Grant RM. (2003) Real-time quantitation of HIV-1 p24 and SIV p27 using fluorescence-linked antigen quantification assays. AIDS 17:629–631.

Kuritzkes DR, Grant RM, Feorino P, Griswold M, Hoover M, Young R, Day S, Lloyd RM, Jr., Reid C, Morgan GF, Winslow DL. (2003) Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the OpenGene DNA Sequencing System. J. Clin. Microbiol. 41:1594–1599.

Murphy EL, Grant RM, Kropp J, Oliveira A, Lee TH, Busch MP. (2003) Increased human T-lymphotropic virus type II proviral load following highly active retroviral therapy in HIV-coinfected patients. J. Acquir. Immune Defic. Syndr. 33:655–656.

Papasavvas E, Grant RM, Sun J, Mackiewicz A, Pistilli M, Gallo C, Kostman JR, Mounzer K, Shull J, Montaner LJ (2003) Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients. AIDS 17:2337–2343.

Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, Deeks SG (2002) Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol. 76:11104–11112.

Deeks SG, Barbour JD, Grant RM, Martin JN (2002) Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 16:201–207.

Deeks SG, Hoh R, Grant RM, Wrin T, Barbour JD, Narvaez A, Cesar D, Abe K, Hanley MB, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK (2002) CD4+ T cell kinetics and activation in human immunodeficiency virus–infected patients who remain viremic despite long-term treatment with protease inhibitor–based therapy. J. Infect. Dis. 185:315–323.

Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO (2002) Time trends in primary HIV-1 drug resistance among recently infected persons. J. Am. Med. Assoc. 288:181–188.

Keppler OT, Welte FJ, Ngo TA, Chin PS, Patton KS, Tsou C-L, Abbey NW, Sharkey ME, Grant RM, You Y, Scarborough JD, Ellmeier W, Littman DR, Stevenson M, Charo IF, Herndier BG, Speck RF, Goldsmith MA (2002) Progress toward a human CD4/CCR5 transgenic rat model for de novo infection by human immunodeficiency virus type 1. J. Exp. Med. 195:719–736.

Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, Grant RM, Halvorsen RA, Schambelan M, McCune JM (2002) Increased thymic mass in circulating naïve CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 16:1103–1111.

Neuenburg JK, Brodt HR, Herndier BG, Bickel M, Bacchetti P, Price RW, Grant RM, Schlote W (2002) HIV-related neuropathology, 1985 to 1999: Rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 31:171–177.

Schweighardt B, Ortiz GM, Grant RM, Wellons M, Miralles GD, Kostrikis LG, Bartlett JA, Nixon DF (2002) Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions. AIDS 16:2342–2344.

Deeks SG, Barbour JD, Grant RM, Martin JN. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002;16:201-207.

Deeks SG, Ho R, Grant RM, et al. CD4+ T Cell Kinetics and Activation in Human Immunodeficiency Virus-Infected Patients Who Remain Viremic Despite Long-term Treatment with Protease Inhibitor-Based Therapy. JID 2002.

Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, Hellmann NS, Chesney M, Busch MP, Kahn JO. Time trends in primary HIV-1 drug resistance among persons recently infected in San Francisco. JAMA. 288(2), 181-188, 2002.

Stoddart CA, Liegler TJ, Mammano F, Linquist-Stepps VD, Hayden MS, Deeks SG, Grant RM, Clavel F, McCune JM. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nature Medicine. 7: 712-718, 2001.

Liegler TJ, Hayden MS, Lee KS, Thounaojam M, Deeks SG, Grant RM. Protease inhibitor resistant HIV-1 from patients with CD4 counts is cytopathic in activated CD4+ lymphocytes. AIDS. 15: 179-184, 2001.

Penn ML, Myers M, Eckstein DA, Liegler TJ, Hayden M, Mammano F, Clavel F, Deeks SG, Grant RM, Goldsmith MA. Primary and recombinant HIV-1 strains resistant to protease inhibitors are pathogenic in mature human lymphoid tissues. AIDS Res and Hum Retrov. 17: 517-523, 2001.

Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med. 344 (7): 472-480, 2001.

Blower SM, Gershengorn HB, and Grant RM. A Tale of Two Futures: HIV and Anti-Retroviral Therapy in San Francisco. Science, 287, 650-654, 2000.

Deeks S and Grant RM. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. Antiviral Therapy. 4 (supplement 3):7-11, 1999.

Deeks S, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4 T cell responses after virologic failure of protease inhibitor based regimens in HIV infected patients. JID 181:946-53, 2000.

Deeks SG, Hecht FM, Swanson M, Elbeik T, Loftus R, Cohen PT, Grant RM. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 13 (6): F35-F43, 1999.

Kaur A, Grant RM, Means RE, McClure H, Feinberg M, Johnson RP. Diverse host response and outcomes following SIVmac239 infection in sooty mangabeys and rhesus macaques. J. Virol. 72(12): 9597-9611, 1998.

Palacios E, Digilio L, McClure HM, Chen Z, Marx PA, Goldsmith MA, Grant RM. Parallel evolution of CCR5-null phenotypes in humans and in natural host of simian immunodeficiency virus. Current Biology. 8:943-946, 1998.

Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Hellmann NS, Bandrapalli NI, Digilio L, Branson B, Kahn JO. Sexual Transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors. N. Engl. J. Med. 339(5):307-311, 1998.

McCune JM, Loftus R, Schmidt DK, Carroll P, Webster D, Swor-Yim LB, Francis IR, Gross BH, Grant RM. High Prevalence of Thymic Tissue in Adults with HIV-1 Infection. J. Clin. Invest. 101(11):2301-2308, 1998.

Grant RM, Piwowar EM, Katongole-Mbidde E, Muzawalu W, Rugera S, Abima J, Stramer S, Kataaha P, Jackson B. Comparison of Saliva and Serum for HIV-1 Antibody Testing in Uganda Using a Rapid Recombinant Assay. Clin. Diag. Lab. Immunol. 3(6):640-644, 1996.

Grant RM, Staprans SI, McLure HM, Johnson RP, Feinberg MB. Viral evolution in sooty mangabeys and rhesus macaques. J. Med. Primatol. 24(4):181, 1995.

Grant RM, Wiley JA, Winkelstein W. The infectivity of the human immunodeficiency virus: estimates from a cohort of homosexual men. J. Inf. Dis. 156:189-193, 1987.

Lang W, Anderson RE, Perkins H, Grant RM, Lyman D, Winkelstein W, Royce R, Levy JA. Clinical, immunologic, and serologic findings in men at risk for acquired immunodeficiency syndrome. San Francisco Men’s Health study. JAMA. 257:326-330, 1987.